GENENTECH, INC.

COLUMVI

Manufacturer:

GENENTECH, INC.

Columvi HCPCS:

J9286

HCPCS Code Descriptor:

Injection, glofitamab-gxbm, 2.5 mg

Category:

J Code

Columvi NDCs:

50242-0127-01, 50242-0125-01

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Columvi:

COLUMVI is a Oncology drug manufactured by GENENTECH, INC. and administered via the Intravenous route of administration. The J Code: J9286 is aligned to the drug COLUMVI.

Columvi is an immunotherapy drug used that is often used to treat treatment-resistant or recurring diffuse large B-cell lymphoma (DLBCL). DLBCL is an aggressive form of non-Hodgkin’s lymphoma, and is one of the most prevalent types of blood cancer in adults. Columvi works by binding certain proteins in the body together and acting as a bridge between cancer cells and your immune system's T cells.

ACCESS PRICING AND MORE BY REGISTERING

J9286 Added Date:

January 1, 2024

J9286 Effective Date:

January 1, 2024

J9286 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Columvi billing and coding information.
Columvi patient assistance information can be found through Genentech at the URL: https://www.columvi.com/financial-support/assistance-options.html
COLUMVI prescribing information can be found at the link below:
Information regarding COLUMVI’s side effects can be found at MedlinePlus